GE renamed Cytiva upon take-over by Danaher
Following the completion of Danahers 19.5bn take-over of GE Healthcare Life Sciences, GEs CDMO arm is renamed Cytiva.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1118 entries already.
Entries by Thomas Gabrielczyk
Making opoids more effective pain killers
/in News/by Thomas GabrielczykLow intrinsic efficacy can explain the reduced side effects of new agonists of the m-opioid receptor a British-Australian reseach team reports.
Apeptico gets EU grant for COVID-19 drug
/in News/by Thomas GabrielczykAustrian APEPTICO has got Horizon 2020 money for accelerated development and clinical use of Solnatide for the treatment of COVID-19 patients
CHMP greenlights Novartis Zolgensma
/in News/by Thomas GabrielczykThe European Medicines Agency EMA has backed eight medicines for approval at its virtual March 2020 meeting.
New resource models human metabolism
/in News/by Thomas GabrielczykScandinavian researchers have created a unified, open-source model providing a genome-wide portrait of human disease metabolism.
Novacyt inks contract on Covid-19 diagnostics
/in News/by Thomas GabrielczykParis-based Novacyt SA has signed a global distribution agreement with Bruker Ltd for its COVID-19 diagnostic test.
AC Immune SA gets Lilly milestone for Alzheimers candidate
/in News/by Thomas GabrielczykAC Immune SA has received a milestone payment of CHF10m from Eli Lilly and Company.
Experts discuss link between sepsis and Covid-19
/in News/by Thomas GabrielczykScientists have discussed a link between Covid-19 and sepsis at a virtual symposium at Charité Berlin that might help reduce the burden of end-stage disease.
Evonik Industries AG establishes production of recombinant collagen
/in News/by Thomas GabrielczykEvonik Industries has established a new animal-free and fermentation-based industrial-scale recombinant collagen production platform.
BioNTech SEs COVID-19 vaccine attracts investment
/in News/by Thomas GabrielczykChinese Fosun Pharma Ltd has made the largest investment in a foreign company for a COVID-19 vaccine development: BioNTechd mRNA vaccine BNT162.